Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06447961
Other study ID # RD23/130
Secondary ID 326731
Status Recruiting
Phase
First received
Last updated
Start date June 18, 2024
Est. completion date August 1, 2026

Study information

Verified date June 2024
Source London North West Healthcare NHS Trust
Contact Laura Monje-Garcia
Phone 0044 20 8453 2656
Email Laura.monje-garcia@nhs.net
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Why? PSYLIVED is a qualitative study that aims to understand the psychological experience of individuals living with inherited colorectal cancer. It addresses the question of how individuals cope emotionally and adapt to the unique challenges they face. This research sheds light on the emotional journey of those with inherited colorectal cancer, potentially leading to improved support services, interventions, and care practices tailored to their needs. The study seeks to enhance the well-being of patients undergoing genetic testing and contribute to better services and support practices. What? PSYLIVED is a qualitative study that will employ reflexive Thematic Analysis methodology to explore the emotional responses and experiences of participants over time. Who? The investigators are interested in interviewing between 30 to 66 individuals who have first-hand experience of being at risk or having an inherited colorectal cancer syndrome. Where? While the study is conducted by the St Mark's Centre for Familial Intestinal Cancer, this study is open to individuals in the UK. Interviews will primarily be conducted via telephone or Microsoft Teams to facilitate accessibility. However, participants residing near London who prefer face-to-face interviews will be offered this option. How? Each participant will take part in a one-hour audio-recorded interview where they will be asked to talk about their experiences. The interview will be recorded, so it can be transcribed word by word. During the transcription, the interview will be anonymised to ensure confidentiality. The responses will then be compared and analysed to create a result summary, along with interviews from other individuals with similar experiences. The study is set to commence in June 2024, with recruitment open for approximately two years.


Description:

STUDY SUMMARY Study Title: Opening Pandora's box: the Psychological Impacts of living with an inherited colorectal cancer predisposition syndrome Internal ref. no. (or short title): PSYLIVED Study Design: Qualitative Study Participants: Adults over 18 with an inherited predisposition or likelihood of inheriting colorectal cancer, offered genetic testing (with and without cancer history) Planned Size of Sample: 30-66 Follow up duration: After the initial interview, participants will not undergo any follow-up assessments. The screening questionnaire will determine the allocated study time-point for analysis. It's important to note that this study is not longitudinal. Planned Study Period: 2024-2026 Research Question: What are the lived experiences and psychological adaptation processes of individuals diagnosed with inherited colorectal cancer over time? PSYLIVED is a qualitative study exploring the psychological experience and long-term adaptation process of people living with inherited colorectal cancer. This project will recruit between 30 to 66 participants which will be allocated at one of the 3 time-points of the long-term adaptation process following the Family Systems Genetic Illness Model as articulated by Miller et al. in 2006 (1). The 3 time-points are: 1. Time-point 1: crisis I- pre-testing phase (before receiving genetic results) 2. Time-point 2: crisis II- post-testing phase (generally up 1 year post genetic testing. However, the team will follow a triage/evaluation system) 3. Time-point 3: long term adaptation phase (generally 1 year post genetic testing and beyond. However, the research team will use a triage/evaluation system) This approach will allow for a rich examination of how participants navigate the psychological impact of their genetic diagnosis across varying temporal contexts. Each of the resulting six distinct datasets, as outlined in Table 1, will undergo individual analyses dedicated to uncovering the psychological adaptation processes at specific time-points. This methodological structure ensures a holistic exploration of the psychological trajectory experienced by individuals living with inherited colorectal cancer. Furthermore, each analysis at distinct time-points will be refined by distinguishing between cancer and non-cancer patients. Subsequently, a synthesis of findings will be conducted through the comparison and combination of individual datasets. By generating a series of analytical sets, the study aims to provide a comprehensive understanding of the psychological journey undertaken by individuals living with inherited colorectal cancer.


Recruitment information / eligibility

Status Recruiting
Enrollment 66
Est. completion date August 1, 2026
Est. primary completion date June 18, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: - Adults aged 18 years or older, residing in the UK. - Diagnosed with inherited colorectal cancer or likely to have inherited colorectal cancer and have been offered genetic testing for this reason. - Possess the capacity to provide informed consent. - Able to communicate in English. Exclusion Criteria: - Under 18 years old. - Unable to communicate in English. - Experience significant learning or communication difficulties. - Reside outside of the UK.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United Kingdom The St Mark's Centre for Familial Intestinal Cancer London

Sponsors (1)

Lead Sponsor Collaborator
London North West Healthcare NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary In-depth understanding of 'lived experiences' of people with or at risk of an inherited colorectal cancer Syndrome Detailed insights into the emotional responses, cognitive processes, and perceptions of individuals throughout their genetic diagnosis journey, providing a rich understanding of their lived experiences.
This is a qualitative study using semi-structured interviews. Data from the qualitative semi-structured interviews will be used to address this outcome. Please note that no score or scale will be used in this research.
2 years.
Secondary Insight into psychological adaptation understanding of how individuals psychologically adapt to the genetic diagnosis over time, identifying patterns of coping, emotional adjustments, and strategies employed to manage the psychological impact.
This is a qualitative study using semi-structured interviews. Data from the qualitative semi-structured interviews will be used to address this outcome. Please note that no score or scale will be used in this research.
2 years
Secondary Contribution to patient wellbeing Knowledge that contributes to improved patient care, by identifying psychological stressors, adaptive approaches, and potential areas for intervention, ultimately improving the overall well-being of individuals and families affected by inherited colorectal cancer.
This is a qualitative study using semi-structured interviews. Data from the qualitative semi-structured interviews will be used to address this outcome. Please note that no score or scale will be used in this research.
2 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT00217737 - Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer Phase 3
Completed NCT00905710 - Chromoendoscopy to Decrease the Risk of Colorectal Neoplasia in Lynch Syndrome N/A
Active, not recruiting NCT02194387 - Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members N/A
Recruiting NCT04909671 - Evaluation of ArTificial Intelligence System (Gi-Genius) for adenoMa dEtection in Lynch Syndrome. N/A
Recruiting NCT04379999 - Atorvastatin ± Aspirin in Lynch Syndrome Syndrome Early Phase 1
Recruiting NCT05692596 - The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
Completed NCT01845753 - Molecular Screening for Lynch Syndrome in Denmark
Completed NCT01216930 - Molecular Screening for Lynch Syndrome in Southern Denmark N/A
Not yet recruiting NCT05963191 - CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch Syndrome N/A
Active, not recruiting NCT02912559 - Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair Phase 3
Recruiting NCT04978350 - Overcoming Barriers to the Uptake of Cascade Screening for Lynch Syndrome: Workbook Feasibility Study N/A
Active, not recruiting NCT03832985 - Pediatric Reporting of Adult-Onset Genomic Results Early Phase 1
Withdrawn NCT04778566 - Evaluating the Cologuard Test for Use in Lynch Syndrome
Completed NCT02570516 - NBI Versus Indigo Carmine During Colonoscopy in Lynch Syndrome N/A
Completed NCT01823471 - I-Scan For Colon Polyp Detection In HNPCC N/A
Recruiting NCT02813824 - Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome Phase 3
Recruiting NCT05078866 - Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients Phase 1/Phase 2
Recruiting NCT03744962 - MSI in Circulatory DNA of Endometrial Cancer
Recruiting NCT04711434 - PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients Phase 3
Completed NCT04131062 - Trial to Compare eConsent With Standard Consent Among Prospective Biobank Participants N/A